Status: Recruiting
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).
Participants needed: 102
Trial details
Phase: Phase 1, Phase 2Age: 40-75Biological sex: AllType: InterventionalSponsor: David WilsonUpdated: Apr 17, 2025Locations: 1
Eligibility criteria
Age 40-75 [+8]
Unable to provide written informed consent and unwilling to comply with protocol... [+7]